However, recent studies have suggested that patients with NPM1 mutation and FLT3-ITD with a low (<0.5) allelic ratio have a similar favorable outcome as patients with NPM1-mutated AML without FLT3-ITD [26,27,28,29]. The gene discussed is FLT3; the disease is acute myeloid leukemia.